Simone Goebel1, Hubertus Maximilian Mehdorn2. 1. Department of Clinical Psychology and Psychotherapy, Institute of Psychology, Christian-Albrechts University, Olshausenstraße 62, 24118, Kiel, Germany. goebel@psychologie.uni-kiel.de. 2. Mehdorn Consilium, Prüner Gang 7, 24103, Kiel, Germany.
Abstract
BACKGROUND: Fear of progression (FoP) is frequent in patients with cancer and of high clinical relevance. Despite the often devastating prognosis of brain cancer, FoP has not yet been assessed in neurooncological patients. OBJECTIVE: The aim of this study was thus the assessment of FoP and its clinical correlates. METHODS: In an ambulatory setting, 42 patients with a primary brain tumour completed the Fear of Progression questionnaire FoP-Q-12. Clinical correlates of FoP were assessed via a variety of measures, including patients' physical state (Karnofsky Performance Status, KPS), cancer-related psychosocial distress (Distress Thermometer, DT), anxiety (General Anxiety Disorder Scale, GAD-7), depression (Patient Health Questionnaire, PHQ-9), Quality of Life (Short Form Health Survey, SF-8), and unmet supportive care needs (Supportive Care Needs Survey, SCNS). RESULTS: Eighteen patients (42%) suffered from high FoP (i.e. scored ≥ 34 in the FoP-Q-12). According to the 12 items of the FoP-Q-12, the greatest fears were worrying about what would happen to their family and being afraid of severe medical treatments. No sociodemographic variables (e.g. age, gender) or medical tumour characteristics (e.g. tumour malignancy, first or recurrent tumour) were related to FoP. Patients with more severe physical symptoms reported higher FoP. Patients with higher FoP were more anxious, more depressed, reported lower Quality of Life, and suffered from more unmet supportive care needs. CONCLUSION: Our results demonstrate that FoP is frequent and of high clinical relevance for neurooncological patients. Its assessment is not sufficiently covered by instruments for assessment of other areas of psychological morbidity (e.g. general anxiety). Moreover, FoP cannot be predicted by objective characteristics of the patients and disease. Thus, the routine screening for FoP is recommended in neurooncological patients. Clinicians should bear in mind that patients with high FoP are likely to suffer from high emotional distress and unmet supportive care needs and initiate treatment accordingly.
BACKGROUND: Fear of progression (FoP) is frequent in patients with cancer and of high clinical relevance. Despite the often devastating prognosis of brain cancer, FoP has not yet been assessed in neurooncological patients. OBJECTIVE: The aim of this study was thus the assessment of FoP and its clinical correlates. METHODS: In an ambulatory setting, 42 patients with a primary brain tumour completed the Fear of Progression questionnaire FoP-Q-12. Clinical correlates of FoP were assessed via a variety of measures, including patients' physical state (Karnofsky Performance Status, KPS), cancer-related psychosocial distress (Distress Thermometer, DT), anxiety (General Anxiety Disorder Scale, GAD-7), depression (Patient Health Questionnaire, PHQ-9), Quality of Life (Short Form Health Survey, SF-8), and unmet supportive care needs (Supportive Care Needs Survey, SCNS). RESULTS: Eighteen patients (42%) suffered from high FoP (i.e. scored ≥ 34 in the FoP-Q-12). According to the 12 items of the FoP-Q-12, the greatest fears were worrying about what would happen to their family and being afraid of severe medical treatments. No sociodemographic variables (e.g. age, gender) or medical tumour characteristics (e.g. tumour malignancy, first or recurrent tumour) were related to FoP. Patients with more severe physical symptoms reported higher FoP. Patients with higher FoP were more anxious, more depressed, reported lower Quality of Life, and suffered from more unmet supportive care needs. CONCLUSION: Our results demonstrate that FoP is frequent and of high clinical relevance for neurooncological patients. Its assessment is not sufficiently covered by instruments for assessment of other areas of psychological morbidity (e.g. general anxiety). Moreover, FoP cannot be predicted by objective characteristics of the patients and disease. Thus, the routine screening for FoP is recommended in neurooncological patients. Clinicians should bear in mind that patients with high FoP are likely to suffer from high emotional distress and unmet supportive care needs and initiate treatment accordingly.
Entities:
Keywords:
Brain tumour; Cancer; Fear of cancer progression; Neurooncology; Psychooncology; Recurrence
Authors: Peter Herschbach; Petra Berg; Andrea Dankert; Gabriele Duran; Ursula Engst-Hastreiter; Sabine Waadt; Monika Keller; Robert Ukat; Gerhard Henrich Journal: J Psychosom Res Date: 2005-06 Impact factor: 3.006
Authors: Patricia A Ganz; Lorna Kwan; Annette L Stanton; Janice L Krupnick; Julia H Rowland; Beth E Meyerowitz; Julienne E Bower; Thomas R Belin Journal: J Natl Cancer Inst Date: 2004-03-03 Impact factor: 13.506
Authors: A Dankert; G Duran; U Engst-Hastreiter; M Keller; S Waadt; G Henrich; P Herschbach Journal: Rehabilitation (Stuttg) Date: 2003-06 Impact factor: 1.113
Authors: Esther N Pijnappel; Willemieke P M Dijksterhuis; Mirjam A G Sprangers; Simone Augustinus; Judith de Vos-Geelen; Ignace H J T de Hingh; Izaak Q Molenaar; Olivier R Busch; Marc G Besselink; Johanna W Wilmink; Hanneke W M van Laarhoven Journal: Support Care Cancer Date: 2022-02-15 Impact factor: 3.359
Authors: Jantine Geertruida Röttgering; Linda Douw; Philip C de Witt Hamer; Mathilde C M Kouwenhoven; Tom Würdinger; Peter M van de Ven; Louise Sharpe; Hans Knoop; Martin Klein Journal: Trials Date: 2022-07-15 Impact factor: 2.728
Authors: Kim Tam Bui; Belinda E Kiely; Haryana M Dhillon; Chris Brown; Kay Xu; Mohsen Shafiei; Prunella Blinman Journal: Support Care Cancer Date: 2021-08-01 Impact factor: 3.603